Pemetrexed-associated urticarial vasculitis

Gilberto Lopes, Vladimir Vincek, Luis E. Raez

Research output: Contribution to journalArticle

Abstract

Pemetrexed (Alimta™, Eli Lilly and Company, Indianapolis, IN) is a structurally novel anti-folate agent. The United States Food and Drug Administration has approved pemetrexed for the treatment of patients with malignant pleural mesothelioma and previously treated patients with locally advanced or metastatic non-small cell lung cancer. In the phase III trials that led to its approval, rash was reported in 17 and 22% of patients receiving pemetrexed alone or in combination with cisplatin. However, little has been published about the characteristics of this rash or about its mechanism. In an attempt to contribute to the growing body of knowledge about this new agent, we describe a case in which a patient developed a rash secondary to urticarial vasculitis associated with pemetrexed.

Original languageEnglish (US)
Pages (from-to)247-249
Number of pages3
JournalLung Cancer
Volume51
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Pemetrexed
Vasculitis
Exanthema
United States Food and Drug Administration
Folic Acid
Non-Small Cell Lung Carcinoma
Cisplatin

Keywords

  • Non-small cell lung cancer
  • Pemetrexed
  • Rash
  • Skin
  • Urticaria
  • Vasculitis

ASJC Scopus subject areas

  • Oncology

Cite this

Pemetrexed-associated urticarial vasculitis. / Lopes, Gilberto; Vincek, Vladimir; Raez, Luis E.

In: Lung Cancer, Vol. 51, No. 2, 02.2006, p. 247-249.

Research output: Contribution to journalArticle

Lopes, G, Vincek, V & Raez, LE 2006, 'Pemetrexed-associated urticarial vasculitis', Lung Cancer, vol. 51, no. 2, pp. 247-249. https://doi.org/10.1016/j.lungcan.2005.10.008
Lopes, Gilberto ; Vincek, Vladimir ; Raez, Luis E. / Pemetrexed-associated urticarial vasculitis. In: Lung Cancer. 2006 ; Vol. 51, No. 2. pp. 247-249.
@article{71c03a26772d48e0b8a27737fd21b167,
title = "Pemetrexed-associated urticarial vasculitis",
abstract = "Pemetrexed (Alimta™, Eli Lilly and Company, Indianapolis, IN) is a structurally novel anti-folate agent. The United States Food and Drug Administration has approved pemetrexed for the treatment of patients with malignant pleural mesothelioma and previously treated patients with locally advanced or metastatic non-small cell lung cancer. In the phase III trials that led to its approval, rash was reported in 17 and 22{\%} of patients receiving pemetrexed alone or in combination with cisplatin. However, little has been published about the characteristics of this rash or about its mechanism. In an attempt to contribute to the growing body of knowledge about this new agent, we describe a case in which a patient developed a rash secondary to urticarial vasculitis associated with pemetrexed.",
keywords = "Non-small cell lung cancer, Pemetrexed, Rash, Skin, Urticaria, Vasculitis",
author = "Gilberto Lopes and Vladimir Vincek and Raez, {Luis E.}",
year = "2006",
month = "2",
doi = "10.1016/j.lungcan.2005.10.008",
language = "English (US)",
volume = "51",
pages = "247--249",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Pemetrexed-associated urticarial vasculitis

AU - Lopes, Gilberto

AU - Vincek, Vladimir

AU - Raez, Luis E.

PY - 2006/2

Y1 - 2006/2

N2 - Pemetrexed (Alimta™, Eli Lilly and Company, Indianapolis, IN) is a structurally novel anti-folate agent. The United States Food and Drug Administration has approved pemetrexed for the treatment of patients with malignant pleural mesothelioma and previously treated patients with locally advanced or metastatic non-small cell lung cancer. In the phase III trials that led to its approval, rash was reported in 17 and 22% of patients receiving pemetrexed alone or in combination with cisplatin. However, little has been published about the characteristics of this rash or about its mechanism. In an attempt to contribute to the growing body of knowledge about this new agent, we describe a case in which a patient developed a rash secondary to urticarial vasculitis associated with pemetrexed.

AB - Pemetrexed (Alimta™, Eli Lilly and Company, Indianapolis, IN) is a structurally novel anti-folate agent. The United States Food and Drug Administration has approved pemetrexed for the treatment of patients with malignant pleural mesothelioma and previously treated patients with locally advanced or metastatic non-small cell lung cancer. In the phase III trials that led to its approval, rash was reported in 17 and 22% of patients receiving pemetrexed alone or in combination with cisplatin. However, little has been published about the characteristics of this rash or about its mechanism. In an attempt to contribute to the growing body of knowledge about this new agent, we describe a case in which a patient developed a rash secondary to urticarial vasculitis associated with pemetrexed.

KW - Non-small cell lung cancer

KW - Pemetrexed

KW - Rash

KW - Skin

KW - Urticaria

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=31344469083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344469083&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.10.008

DO - 10.1016/j.lungcan.2005.10.008

M3 - Article

C2 - 16360237

AN - SCOPUS:31344469083

VL - 51

SP - 247

EP - 249

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -